Ribociclib and Letrozole Treatment in Ovarian Cancer
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Gynecologic Oncology Group
- Study ID
- NCT03673124
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Low Grade Serous Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ribociclib — DRUG600 mg by mouth daily for 21 days followed by 7 days off treatment
- Letrozole — DRUG2.5 mg by mouth daily
Study Details
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
Key Dates
- Start date
- May 20, 2019
- Status verified
- Dec 2025
- Primary completion
- Dec 23, 2024
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 51 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: Ribociclib and letrozoleRibociclib 600mg oral daily for 3 weeks then 1 week off plus Letrozole 2.5 mg oral daily
Primary Outcome Measure
Objective Response Rate (ORR) [ Time Frame: Every 3 cycles during treatment period and at least 4 weeks after the first observation of a complete or partial response assessed up to approximately 55.9 months. The average study treatment time was 16.4 months. ]